Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Nivolumab Monotherapy or in Combination Therapy

ESMO Congress 2022


Marleen Kok, MD, PhD, of The Netherlands Cancer Institute in Amsterdam, discusses the initial results from the BELLINI trial, which tested whether short-term preoperative nivolumab, either as monotherapy or in combination with low-dose doxorubicin or novel immunotherapy combinations, can induce immune activation in patients with early-stage triple-negative breast cancer with tumor-infiltrating lymphocytes (Abstract LBA13).


Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The purpose of the Bellini study is to test the value of immune checkpoint innovation in early stage, triple-negative breast cancer without chemotherapy, in those tumors where there are TILs: Tumor infiltrating lymphocytes. The last years we have seen meta-analysis and retrospective data: the triple-negative breast cancer patients where you have TILs in the tumor at a high level, that those women have a very good outcome, even without chemotherapy. Also, related to lymphocytes is the introduction of checkpoint blockade pembrolizumab for stage two and stage three, triple-negative breast cancer, in addition to the chemotherapy. So those two developments are great for our patients, however, they come with new questions: who should we treat with immune checkpoint blockade? Who can be treated with immunotherapy without chemotherapy? How do we predict those good responders? And can we also give a bit less treatment, so either immunotherapy or chemotherapy or the shorter duration? All those topics are being studied in the Bellini study. So the Bellini is a basket study, where we make small baskets of 15 triple-negative breast cancer patients, all that have TIL levels above 5%. In the first basket, the patients were treated with nivolumab (anti-PD-1) for treatment durations of four weeks, followed by chemotherapy or their surgery. In the second basket, patients receive nivolumab, plus one shot of low-dose ipilimumab (also for four weeks), followed by chemotherapy or surgery. And before the chemotherapy, we made an MRI and also a biopsy or stake. If you look at the adverse events, the treatment was, in general, tolerated pretty well, with the well known side effects for immune checkpoint blockage that we have seen before in cancer patients: with a relatively high number of patients suffering from thyroid problems, which has also been reported for other breast cancer trials. Related to the efficacy, since this is a window trial, we have chosen a biological endpoint, meaning an enhancement of immune activation, meshed by CD8 levels (studied using immunochemistry), or increase in interferon gamma (using gene expression). And we were aiming for doubling of those values. So can we, within four weeks of treatment, enhance the immune activation? And that seems to be the case. So in the first basket, 15 patients were treated; in the second basket, 16 patients. And more than half of the patients in both baskets experienced such an immune activation, by a doubling of CD8 T cells or a doubling of interferon gamma. And thereby both cohorts met the primary endpoint of the clinical trial. The secondary endpoint was the radiological response: of the 30 cases, seven patients had a partial response on MRI after only four weeks of treatment, which was more than we expected upfront. Of those seven cases, three patients were in the nivolumab cohort and four patients in the nivolumab-ipilimumab cohort. Interestingly, we've seen that all patients with such a partial response had TIL levels above 40%, suggesting that if you have higher levels of TIL, the more likely you are to respond to the treatment. Secondly, we also looked at ctDNA levels: so can we see a drop in ctDNA levels, circulating tumor DNA in the blood of those patients? And you see that around 25% of the patients indeed have clearance of ctDNA with only four weeks of treatment. So in conclusion, this exploratory trial suggest that there is a subgroup of patients that can be treated with immunotherapy alone, without chemotherapy, as measures using immune activation. Also, we've seen that around 20% of the patients showed a partial response after four weeks of treatment and 25% of the patient showed ctDNA clearance. Currently we're working on single-cell, RNA sequencing analysis to dissect the difference between nivolumab and nivolumab plus ipilimumab; and also validation cohorts are ongoing for patients with TIL levels above 50%, where we treat for six weeks and then all patients goes to surgery, to really assess the pathological response after immune checkpoint blockade in early stage, triple-negative breast cancer.

Related Videos

Head and Neck Cancer

Jean-Pascal Machiels, MD, PhD, on Head and Neck Cancer: Recent Data on Pembrolizumab and Chemoradiation Therapy

Jean-Pascal Machiels, MD, PhD, of Belgium’s Cliniques universitaires Saint-Luc (UCLouvain), discusses the primary results of the phase III KEYNOTE-412 study of pembrolizumab plus chemoradiation therapy (CRT) vs placebo plus CRT for patients with locally advanced head and neck squamous cell carcinoma (Abstract LBA5).

Breast Cancer

Laurence Buisseret, MD, PhD, on Triple-Negative Breast Cancer: Chemoimmunotherapy With or Without an Anti-CD73 Antibody

Laurence Buisseret, MD, PhD, of Belgium’s Institut Jules Bordet, discusses phase II results from the SYNERGY trial, which tested first-line chemoimmunotherapy of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer. Although adding oleclumab to durvalumab with chemoimmunotherapy did not increase the clinical benefit rate at week 24, research is ongoing to better understand the mechanisms of response and resistance to this study combination (Abstract LBA17).

Lung Cancer

Charles Swanton, PhD, on Non–Small Cell Lung Cancer Induced by Air Pollution

Charles Swanton, PhD, of The Francis Crick Institute, discusses a newly discovered mechanism of action for air pollution–induced non–small cell lung cancer in which particles linked to climate change appear to promote cancerous changes. The finding might pave the way for new potential approaches to lung cancer prevention and treatment (Abstract LBA1).

Pancreatic Cancer

Christelle de la Fouchardiere, MD, on Pancreatic Ductal Adenocarcinoma: Phase III Trial Results With Gemcitabine Plus Paclitaxel

Christelle de la Fouchardiere, MD, of France’s Centre Léon Bérard, discusses phase III findings from the PRODIGE 65–UCGI 36–GEMPAX UNICANCER study, which evaluated whether the combination of gemcitabine and paclitaxel improves overall survival compared with gemcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma after FOLFIRINOX failure or intolerance (Abstract LBA60).

Breast Cancer

Matthew P. Goetz, MD, on Breast Cancer: Interim Survival Results With Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor

Matthew P. Goetz, MD, of Mayo Clinic, discusses recent data from the MONARCH 3 trial of patients with advanced hormone receptor–positive, HER2-negative breast cancer. The study, a second interim analysis, showed that longer overall survival was observed in both the intention-to-treat group as well as in the subgroup with visceral disease. However, neither met the threshold for statistical significance, and further analyses are planned when more data can be reported. (Abstract LBA15).